New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Tools›Compare›Chonluten vs IGF-1 LR3

Chonluten vs IGF-1 LR3

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Anabolic & IGF
IGF-1 LR3
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
20–30 hours
Admin Route
SubQ, Oral
SubQ, IM
Research
—
—
Typical Dose
10 mg per day
40–80 mcg
Frequency
Daily for 10–30 days
Once daily or split twice daily
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Direct muscle hypertrophy via IGF-1R stimulation
  • Muscle hyperplasia (new fiber formation) — unique among peptides
  • Rapid gains in lean muscle mass
  • Accelerated recovery from training and injury
  • Increased nutrient uptake by muscle cells
  • Fat oxidation enhancement
  • Bone density improvement
  • Cartilage and connective tissue repair
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Hypoglycemia (significant risk — insulin-like activity)
  • Acromegaly-like effects with excessive long-term use
  • Jaw and hand swelling
  • Organ hypertrophy with extreme doses
  • +2 more
Stacks With
—
—